If the world already had a pan-coronavirus vaccine in March 2020, it could have served as a mitigation tool until vaccines specific to SARS-CoV-2 could be developed.
A 7-year-old Golden Retriever named Scout and UW–Madison’s School of Veterinary Medicine are already stealing the show in the run-up to the Super Bowl. Scout’s story, in the form of a 30-second commercial for WeatherTech, has already received an overwhelming reaction since it was first released on Tuesday.
As details of the virus and its effects continue to emerge, UW physicians, epidemiologists, public health officials, scientists and communication experts addressed questions and concerns from the public.
Measuring changes in the speed of electrical signals along nerves connecting the eyes to the brain may accurately reflect recovery from myelin loss in multiple sclerosis (MS), according to new UW-Madison research.
Dogs started receiving a vaccine against cancer this week in a clinical trial at UW-Madison. If the vaccine works in dogs, it may not only provide a new strategy for addressing a critical canine health concern, it might also work in people.
Using a new tool they call FluVision, UW-Madison researchers can witness an influenza infection in a living animal in action, helping them better understand what happens when a virus infects the lungs and the body responds.
New research shows that in long-lived animals, renewed but thin myelin sheaths are enough to restore impaired nervous systems and can do so for years after the onset of disease.
Avian influenza has made headlines in Wisconsin and several other states in recent weeks. The University of Wisconsin-Madison and the Wisconsin Veterinary Diagnostic Laboratory (WVDL) are on the front line in responding to and understanding the virus and providing critical testing for food producers and commercial and private flock owners.